Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024

Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr

Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023

Briefs: Krsnaa Diagnostics and Solara Active Pharma Sciences

Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

Solara Active Pharma elevates Arun Kumar Baskaran to the post of CFO

Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies

Solara announces restoration of CEP for ranitidine hydrochloride

Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site